Secura Bio

Corporate Profile

Secura Bio is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada, Secura Bio has operations in the U.S. and offices in San Diego.


Joseph M. Limber

President & Chief Executive Officer

Mr. Limber has 40 years of experience in Life Sciences and was a co-founder of Secura. His leadership and value creation experience include President/CEO roles at Sequus (acquired by J&J), Praecis (acquired by Glaxo), Aclara Biosciences (acquired by LabCorp), Prometheus Laboratories (acquired by Nestle Health Science) and Genoptix (acquired by NeoGenomics). Mr. Limber’s management experience also includes senior roles at Ciba-Geigy (now Novartis) and Syntex (now Roche).

Mr. Limber’s track record includes building successful commercial organizations, relaunching high-value therapeutics, successful turnarounds and consistently delivering value to investors. Under his leadership, $3.0 billion of financings (private and public), product and M&A transactions were completed. Mr. Limber is a member of the Board of Directors of Secura Bio, Inc. and Xoma Corporation.

Mark E. Spring

Chief Financial Officer

Mr. Spring has 25 years of experience in Life Sciences and was a co-founder of Secura. His financial leadership experience includes capital raising, financial reporting and controls for private and public, domestic and multinational companies. Prior to Secura, Mr. Spring was Chief Financial Officer for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless and Genoptix. In addition, Mr. Spring has extensive M&A experience with significant roles in transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. Prior to his CFO roles, he also held senior level financial positions at Baxter Healthcare and Price Waterhouse.

Mr. Spring earned a B.A. in Business Administration from Monmouth College. He also completed post-graduate studies at the University of Texas, Dallas and is a Certified Public Accountant (active).

Brett K.E. Lund, J.D., M.B.A.

Chief Legal Officer

Mr. Lund has 20 years of experience and was a co-founder of Secura. He is admitted to practice law in California and North Carolina and has extensive corporate, intellectual property, licensing, employment and private and public market financing experience. Prior to Secura, Mr. Lund was Chief Legal Officer at Genoptix and at Gevo, Inc. In addition, Mr. Lund has leadership, operating, and transaction experience as CEO of Agarigen, Inc. where he led the company’s sale to Intrexon, Inc. His prior experience also includes legal roles at Syngenta Biotechnology and at Ford Motor Company’s Wingcast subsidiary. Mr. Lund was a corporate attorney at the law firm of Cooley LLP.

Mr. Lund earned a J.D. from Duke University School of Law, an M.B.A. from the Fuqua School of Business, Duke University and a B.A. from the University of California, San Diego. He is a Certified Licensing Professional.

Juan Estruch

Head of Corporate Development

Dr. Estruch has over 25 years of experience in Life Sciences and was a co-founder of Secura. He has extensive experience in product assessment, corporate strategy, corporate development and served in increasingly senior management roles. Prior to Secura, Dr. Estruch served in senior positions or as head of corporate development for Ciba-Geigy, Novartis, Diversa, Prometheus and Genoptix. He has a proven track record for identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch.

Dr. Estruch earned a Ph.D. in Biochemistry and Molecular Biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

David M. Cohan, M.D.

Chief Medical Officer

Dr. Cohan has over 20 years of experience in Life Sciences. Prior to Secura, Dr. Cohan co-led the oncology program at Alkermes. Prior to Alkermes, Dr. Cohan held leadership roles at Amgen helping manage both solid tumor and hematologic oncology products. Prior to joining industry, Dr. Cohan was an Assistant Professor and Attending Surgeon in the Department of Head & Neck and Plastic & Reconstructive Surgery at Roswell Park Cancer Institute. Dr. Cohan is a Diplomate of the American Board of Surgery and a fellow of the American College of Surgeons and maintains active Board Certification in General Surgery. Dr. Cohan is an elected Member of the American Head & Neck Society (AHNS) and The Society of Surgical Oncology (SSO). He has authored numerous peer reviewed publications on melanoma, head & neck cancer, leukemia, and lymphoma.

Dr. Cohan graduated from Yale College and The Stanford University School of Medicine.

William J. Davis

Senior Vice President — Commercial Operations

Mr. Davis has 20+ years of Life Science experience. He has deep oncology biopharmaceutical sales and marketing experience and a track record for leading successful sales team deployment, managed care strategies, and GPO partnerships. Mr. Davis’ broad commercial therapeutics experience includes roles of increasing responsibility at Amgen, Johnson & Johnson and Pharmacia/Upjohn. At Amgen, Bill’s responsibilities included: U.S. & Global Marketing/Commercial Strategy Development, U.S. Commercial Lead for Aranesp, and Global Leadership & Performance Decision Sciences - a CEO initiative to coordinate efficiency of senior-level executives across the company. Mr. Davis' prior responsibilities include sales leadership and product launches across community, institution and government segments.

Mr. Davis earned a B.A. in Business Administration from California State University, San Bernadino.

Investor Contact

Mark Spring

Phone: (858) 251-1414